Last edition
News about Global Pharma
Activities are currently underway to finalize the seamless Phase 2/3 master protocol design that will evaluate multiple investigational therapies for the treatment of pancreatic cancer. An intent of the study is to produce registration-enabling data.
Global Pharma | 15/05/2024 | By Manvi | 545
Aurora Cannabis Appoints Rajesh Uttamchandani to Board of Directors
Rajesh Uttamchandani joins the Board with notable expertise in strategy development, innovation, human capital and governanc
Global Pharma | 15/05/2024 | By Manvi | 995
Aldevron Inks Strategic Partnership with Acuitas Therapeutics
Aldevron has forged a strategic partnership with Acuitas Therapeutics, Inc., a private biotechnology company specializing in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles (LNPs).
Global Pharma | 15/05/2024 | By Aishwarya | 864
FogPharma and ARTBIO to Co-Develop HEARTS for Treatment of Cancer
FogPharma has collaborated with ARTBIO to co-develop Helicon-enabled ARTs (HEARTs) to transform outcomes for patients with multiple types of cancer.
Global Pharma | 15/05/2024 | By Aishwarya | 315
NEOsphere Join Hands with Kymera Therapeutics for Novel Molecular Glue Target Discovery
NEOsphere Biotechnologies has partnered with Kymera Therapeutics, Inc. focused on unlocking undrugged or poorly drugged disease-causing protein targets that can be only or best addressed by Targeted Protein Degradation.
Global Pharma | 15/05/2024 | By Aishwarya | 371
SprintRay Unveils Pro 2 Desktop 3D Printer and Next-Gen Resins Revolutionising Dental Care
The Pro 2, boasting cutting-edge Optical Panel technology, sets a new standard in precision and throughput.
Global Pharma | 15/05/2024 | By Abha | 622
FDA Accepts PTC Therapeutics' Application for Upstaza Gene Therapy for AADC Deficiency
The BLA acceptance comes with a Priority Review designation, highlighting the urgent need for therapeutic options for patients suffering from AADC deficiency.
Global Pharma | 15/05/2024 | By Abha | 1155
Verismo Therapeutics Gets IND Clearance from FDA for SynKIR-310 in Relapsed/Refractory B-cell NHL
Verismo Therapeutics announced that it has received a notification from the US Food and Drug Administration (FDA) that the Phase 1 clinical trial of SynKIR™-310 for the investigation of NHL may proceed.
Global Pharma | 14/05/2024 | By Manvi | 619
UroShield is an ultrasound-based product designed to prevent bacterial colonization and biofilm on indwelling urinary catheters and increase antibiotic efficacy, ultimately reducing the incidence of catheter-associated urinary tract infections (CAUTI).
Global Pharma | 14/05/2024 | By Manvi | 419
Boehringer Ingelheim Teams Up with Quallent to Expand Access to adalimumab-adbm Injection
Boehringer Ingelheim has signed a deal with Quallent Pharmaceuticals to help expand patient access to citrate-free adalimumab-adbm, Boehringer's biosimilar to Humira (adalimumab), in the US.
Global Pharma | 14/05/2024 | By Aishwarya | 875
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy